Lite Strategy (LITS) Current Assets (2011 - 2026)
Lite Strategy (LITS) posted quarterly Current Assets of $11.0 million for Q1 2026, down 47.18% year-over-year from $20.8 million in Q1 2025, and up 0.58% quarter-over-quarter from $10.9 million in Q4 2025.
Lite Strategy (LITS) Current Assets (2011 - 2026) Analysis & Trends
Lite Strategy's Current Assets history runs 16 years deep, the most recent figure standing at $11.0 million for Q1 2026.
- In Q1 2026, Current Assets fell 47.18% year-over-year to $11.0 million; the TTM figure through Mar 2026 stood at $11.0 million (down 47.18% YoY), while the FY2025 annual figure was $18.3 million, down 55.15% from the prior year.
- Current Assets for Q1 2026 stood at $11.0 million, up from $10.9 million in the prior quarter.
- The five-year high for Current Assets was $183.5 million in Q1 2022, with the low at $10.9 million in Q4 2025.
- The 5-year median for Current Assets is $59.4 million (2024), against an average of $73.1 million.
- The sharpest annual moves came in 2022 and 2024: Current Assets increased 3.91% in 2022, then plunged 68.62% in 2024.
- Lite Strategy's Current Assets stood at $133.4 million in 2022, then plunged by 50.41% to $66.2 million in 2023, then plunged by 63.15% to $24.4 million in 2024, then sank by 55.25% to $10.9 million in 2025, then gained by 0.58% to $11.0 million in 2026.
- Business Quant data shows LITS's Current Assets at $11.0 million in Q1 2026, $10.9 million in Q4 2025, and $13.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - | 10.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.98 Mn |
| Dec 31, 2025 | 10.91 Mn |
| Sep 30, 2025 | 13.24 Mn |
| Jun 30, 2025 | 18.29 Mn |
| Mar 31, 2025 | 20.78 Mn |
| Dec 31, 2024 | 24.39 Mn |
| Sep 30, 2024 | 27.75 Mn |
| Jun 30, 2024 | 40.77 Mn |
| Mar 31, 2024 | 59.37 Mn |
| Dec 31, 2023 | 66.17 Mn |
| Sep 30, 2023 | 88.42 Mn |
| Jun 30, 2023 | 107.53 Mn |
| Mar 31, 2023 | 120.48 Mn |
| Dec 31, 2022 | 133.45 Mn |
| Sep 30, 2022 | 148.91 Mn |
| Jun 30, 2022 | 167.13 Mn |
| Mar 31, 2022 | 183.47 Mn |
| Dec 31, 2021 | 200.73 Mn |
| Sep 30, 2021 | 167.36 Mn |
| Jun 30, 2021 | 164.82 Mn |